Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Propentofylline
Le Vet Beheer B.V.
QC04AD90
Propentofylline
100 mg/tablet
Tablet
POM: Prescription Only Medicine as defined in relevant national legislation
Dogs
propentofylline
Cardiovascular
Authorised
2015-05-29
Health Products Regulatory Authority 06 April 2020 CRN009CCD Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Canergy 100 mg tablets for dogs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE: Propentofylline 100 mg EXCIPIENTS: For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. Light brown with brown spots, round and convex flavoured tablet with a cross-shaped break line on one side. The tablets can be divided into 2 or 4 equal parts. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the improvement of peripheral and cerebral vascular blood circulation. For improvement in dullness, lethargy and overall demeanour in dogs. 4.3 CONTRAINDICATIONS Do not use in dogs weighing less than 5 kg. Do not use in known cases of hypersensitivity to the active substance or to any of the excipients. See also section 4.7. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals Specific diseases (e.g. kidney disease) should be treated accordingly. Consideration should be given to rationalising the medication of dogs already receiving treatment for congestive heart failure or bronchial disease. In the case of renal failure, the dose should be reduced. The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals. Special precautions to be taken by the person administering the veterinary medicinal product to animals Care should be taken to avoid accidental ingestion. In the event of accidental ingestion of the tablets, seek medical advice immediately and show the package leaflet or the label to the physician. Wash hands after use. Health Products Regulatory Authority 06 April 2020 CRN009CCD Page 2 of 4 Any unused tablet portion should be returned to the open blister and inserted back into the carton to be used for the next administration. 4.6 ADVERSE REACTIONS (F Read the complete document